MeSH D002294 - squamous cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D002294:Â
Squamous cell carcinoma
D000077277:Esophageal squamous cell carcinoma
D001913:Bowen's disease
0 Companies
0 Drugs
Success rate
D000077195:Squamous cell carcinoma of head and neck
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim | Afatinib | Gilotrif | 2026-01-13 | 2013-07-12 |  |  |
| Afatinib | Giotrif |  | 2013-09-25 |  |  | |
| Merck Sharp & Dohme | Cetuximab | Erbitux |  | 2004-06-29 |  |  |
| Pembrolizumab | Keytruda |  | 2014-09-04 | $26,163 M | Q2/23-Q1/24 | |
| Eli Lilly | Cetuximab | Erbitux |  | 2004-02-12 | $611.2 M | Q2/23-Q1/24 |
| Barr Pharmaceuticals | Hydroxyurea | Hydroxyurea |  | 1998-07-30 |  |  |
| Bristol Myers Squibb | Nivolumab | Nivolumab BMS |  | 2015-07-20 |  |  |
| Nivolumab | Opdivo |  | 2014-12-22 | $8,885 M | Q2/23-Q1/24 | |
| Nivolumab, Relatlimab | Opdualag |  | 2022-03-18 | $716 M | Q2/23-Q1/24 | |
| Endo | Hydroxyurea | Hydroxyurea |  | 1999-02-24 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%47/75
Phase 2
20%21/106
Phase 3
43%15/35
Approved: 11Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use